Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Optimer Looking At Prophylaxis As Next Frontier For C. Difficile Agent Dificid

Executive Summary

Optimer's next step, having garnered the expected FDA approval of its Clostridium difficile antibiotic Dificid (fidaxomicin), will be to consider prophylaxis as a possible road to an expanded market for the macrolide antibiotic.

You may also be interested in...



Optimer's Early Sales Of Dificid Topping Analyst Projections

The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.

Optimer's Early Sales Of Dificid Topping Analyst Projections

The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.

Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators

EU's scientific advisory panel also recommends approval for Takeda's azilsartan and Tibotec's rilpivirine, and grants positive opinions on new indications for Bayer/Johnson & Johnson's rivaroxaban and Alexion's eculizumab.

Related Content

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel